AstraZeneca announced it has agreed with the European Commission to provide up to 400 million doses of the AZD1222 vaccine, which it is developing jointly with the University of Oxford against COVID-19.
The British-Swedish multinational pharmaceutical and biopharmaceutical company said in a statement: “The European Commission’s first agreement on a vaccine against COVID-19 ensures that all EU Member States have access to the non-profit vaccine during the pandemic”.
The agreement is a consequence of AstraZeneca’s existing agreement with the European Alliance for Exclusive Vaccines (led by Germany, France, Italy and the Netherlands).
The new agreement will give all EU member states, including Greece, equal access to the vaccine on a non-profit basis during the pandemic. It also allows EU Member States to redirect batches to other European countries.